Skip to main content
Premium Trial:

Request an Annual Quote

GE Healthcare, BGI Partner on Stem Cell Research

NEW YORK (GenomeWeb News) – GE Healthcare and BGI today announced a multi-year research collaboration to explore the underlying genetic variation between ethnically diverse human stem cell lines.

The goal of the deal, whose terms were not disclosed, is to advance the use of stem cell-derived assays in drug discovery and toxicity testing.

The partnership is being carried out in two projects. In the first, BGI will sequence and perform epigenetic analyses of cardiomyocytes and hepatocytes supplied by GE Healthcare Life Sciences in order to map the genetic variation across an ethnically diverse range of stem cell lines, and to investigate the changes that occur during differentiation into specific cell types. This will result in a better understanding of cell models used in drug development, they said.

In the second project, GE will provide BGI an IN Cell Analyzer 2000 system for high content cellular imaging analysis. BGI will use the platform to investigate gene function for a library of cell types that have been previously sequenced by overexpressing or blocking the activity of single genes and observing the effect in select cell populations

"As the pharmaceutical industry seeks to reduce the cost of drug development and to bring more effective, safer drugs to market, the availability of more biologically relevant and predictive cell models is becoming increasingly important," Amr Abid, general manager of Cell Technologies, GE Healthcare Life Sciences, said in a statement. "Our long term vision is to help this process by developing a broad range of Cytiva stem-cell derived assays, to include cell types from a wide diversity of ethnic backgrounds.

In collaboration with BGI, the two partners "will advance our understanding of different stem cell lines, which in turn may in the future help in the global drive to develop new, safer and more effective medicines," he added.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.